StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)

Close on Nov 17, 2026Market cap $13.19MP/E –Yield –

Lipocine price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Lipocine's price to book ratio was 0.6× on Nov 11, 2026, against 1.3× a year earlier. Over the last 5 years it ranged from 0.5× to 4.2×, with a median of 1.0×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.6×−2.5
2025Dec 31, 20253.1×+1.7
2024Dec 31, 20241.4×+0.7
2023Dec 29, 20230.7×−0.3
2022Dec 30, 20220.9×−1.7
2021Dec 31, 20212.7×−3.5
2020Dec 31, 20206.2×+4.9
2019Dec 31, 20191.3×−1.1
2018Dec 31, 20182.4×−0.7
2017Dec 29, 20173.1×+0.7
2016Dec 30, 20162.4×−2.7
2015Dec 31, 20155.1×+2.9
2014Dec 31, 20142.2×−0.3
2013Dec 31, 20132.5×–

More Lipocine figures

See a number that looks wrong?